The futility study-Progress over the last decade
We review the futility clinical trial design (also known as the non-superiority design) with respect to its emergence and methodologic developments over the last decade, especially in regard to its application to clinical trials for neurological disorders. We discuss the design's strengths as a programmatic screening device to weed out unpromising new treatments, its limitations and pitfalls, and a recent critique of the logic of the method..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 45(2015), Pt A, Seite 69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levin, Bruce [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1016/j.cct.2015.06.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1968092706 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1968092706 | ||
| 003 | DE-627 | ||
| 005 | 20220216124028.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2015.06.013 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1968092706 | ||
| 035 | |a (DE-599)GBVOLC1968092706 | ||
| 035 | |a (PRQ)c892-8dc6d2e5a536ebde76c319b35b35efa8f29d209241e3f3f24555c7ebcfe3b5d90 | ||
| 035 | |a (KEY)0092019320150000045000000069futilitystudyprogressoverthelastdecade | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Levin, Bruce |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The futility study-Progress over the last decade |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a We review the futility clinical trial design (also known as the non-superiority design) with respect to its emergence and methodologic developments over the last decade, especially in regard to its application to clinical trials for neurological disorders. We discuss the design's strengths as a programmatic screening device to weed out unpromising new treatments, its limitations and pitfalls, and a recent critique of the logic of the method. | ||
| 540 | |a Nutzungsrecht: Copyright © 2015 Elsevier Inc. All rights reserved. | ||
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d New York, NY [u.a.] : Elsevier, 2005 |g 45(2015), Pt A, Seite 69 |w (DE-627)482838043 |w (DE-600)2182176-8 |w (DE-576)116797290 |x 1551-7144 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2015 |g number:Pt A |g pages:69 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.cct.2015.06.013 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26123873 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4305 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 45 |j 2015 |e Pt A |h 69 | ||